Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Kongnyuy, Daniel Halpern, Corinne Liu, K. Kosinski, D. Habibian, A. Corcoran, A. Katz (2017)
3-T multiparametric MRI characteristics of prostate cancer patients suspicious for biochemical recurrence after primary focal cryosurgery (hemiablation)International Urology and Nephrology, 49
H. Ahmed, A. Bosaily, L. Brown, R. Gabe, R. Kaplan, M. Parmar, Y. Collaco-Moraes, Katie Ward, R. Hindley, A. Freeman, A. Kirkham, R. Oldroyd, C. Parker, M. Emberton (2017)
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory studyThe Lancet, 389
E. Becher, H. Lepor (2020)
Oncological control following partial gland ablation for intermediate-risk prostate cancer.Urologic oncology
H. Lepor, Samuel Gold, James Wysock (2018)
Focal Ablation of Prostate Cancer.Reviews in urology, 20 4
(2017)
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating Nuclear Medicine and Molecular Imaging 1 3 confirmatory study
A. Rosenkrantz, S. Scionti, Savvas Mendrinos, S. Taneja (2011)
Role of MRI in minimally invasive focal ablative therapy for prostate cancer.AJR. American journal of roentgenology, 197 1
E Felker (2019)
10.2214/AJR.19.21637.UtilityAJR Am J Roentgenol, 6
James Wysock, E. Becher, Rozalba Gogaj, Nermarie Velázquez, H. Lepor (2020)
Early oncological control following partial gland cryo-ablation: a prospective experience specifying reflex MRI guided biopsy of the ablation zoneProstate Cancer and Prostatic Diseases, 24
Alexander Kenigsberg, Elton Llukani, F. Deng, J. Melamed, Ming Zhou, H. Lepor (2018)
The Use of Magnetic Resonance Imaging to Predict Oncological Control Among Candidates for Focal Ablation of Prostate Cancer.Urology, 112
(2017)
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating 200 Nuclear Medicine and Molecular Imaging
H. Poel, R. Bergh, E. Briers, P. Cornford, A. Govorov, A. Henry, T. Lam, M. Mason, O. Rouvière, M. Santis, P. Willemse, H. Poppel, N. Mottet (2018)
Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018.European urology, 74 1
(2018)
two-year Outcomes Following Focal Laser Ablation of Localized Prostate
Brian Chao, Elton Llukani, H. Lepor (2018)
Two-year Outcomes Following Focal Laser Ablation of Localized Prostate Cancer.European urology oncology, 1 2
E. Felker, S. Raman, D. Lu, Mitch Tuttle, D. Margolis, Fuad Elkhoury, J. Sayre, L. Marks (2019)
Utility of Multiparametric MRI for Predicting Residual Clinically Significant Prostate Cancer After Focal Laser Ablation.AJR. American journal of roentgenology
M. Valerio, Y. Cerantola, S. Eggener, H. Lepor, T. Polascik, A. Villers, M. Emberton (2017)
New and Established Technology in Focal Ablation of the Prostate: A Systematic Review.European urology, 71 1
PurposeThe goal of partial gland ablation (PGA) is to eradicate focal lesions of clinically significant prostate cancer (csPCa) with minimal adverse impact on functional outcomes. The primary objective of this study is to characterize the performance of 18F-Fluciclovine PET imaging for detection of prostate cancer following PGA.Materials and MethodsSubjects 2 years following primary partial gland cryoablation (PPGCA) were invited to participate in an IRB-approved study providing they met the following inclusion criteria: a single reported mpMRI region of interest (ROI) concordant with biopsy Gleason Grade Group (GGG) < 4, no gross extra-prostatic extension on mpMRI, and no GGG > 1 or GGG 1 with a core length > 6 mm on contralateral systematic biopsy. 18F-Fluciclovine PET MRI imaging of the prostate was performed followed by in and out-of-field biopsies.ResultsTwenty-seven men who met eligibility criteria participated in the prospective study. In-field and out-of-field csPCa recurrence rate was 7.4% and 22.2%, respectively. The sensitivity and positive predictive value of mpMRI and PET imaging did not reach performance to reliably inform who should undergo prostate biopsy.ConclusionAt 2 years following PPGCA, the rate of in-field csPCa was exceedingly low indicating a limited role for imaging to inform in-field biopsy decisions. The csPCa detection rate of out-of-field recurrence was 22% which provides an opportunity for imaging to inform out-of-field biopsy decisions. Based on our findings, 18F-Fluciclovine PET MRI cannot be used to inform who should undergo out-of-field prostate biopsy at 2 years following PPGCA.
Nuclear Medicine and Molecular Imaging – Springer Journals
Published: Aug 1, 2022
Keywords: Prostate cancer; PET imaging; Fluciclovine; Cryoablation; Focal therapy
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.